Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy

NCT01009294 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT01009294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01009294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy
Lead sponsor
PTC Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
January 13, 2010
Completion date
March 23, 2010
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

becker muscular dystrophy, duchenne muscular dystrophy